[1] Iftikhar M, Frey J, Shohan MJ, Malek S, Mousa SA (2021) Current and emerging therapies for Duchenne muscular dystrophy and spinal muscular atrophy. Pharmacol Ther 220:107719. https://doi.org/10.1016/j.pharmthera.2020.107719
[2] Cunha T.A, Grilo EC, Costa ADS, Vermeulen-Serpa K.M, Leite-Lais L, Dourado-Júnior MET, Brandão-Neto J, Vale SHL. When age matters: boys with Duchenne muscular dystrophy have growth delay and a fat mass accumulation, as they get older. Research, Society and Development, [S. l.], v. 10, n. 6, p. e44010615922, 2021. DOI: 10.33448/rsd-v10i6.15922
[3] MacKintosh EW, Chen ML, Benditt JO (2020) Lifetime Care of Duchenne Muscular Dystrophy. Sleep Med Clin 15:485–95. https://doi.org/10.1016/j.jsmc.2020.08.011
[4] Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A et al. (2018) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol 17:251–67. https://doi.org/10.1016/S1474-4422(18)30024-3
[5] Deng J, Zhang J, Shi K, Liu Z. Drug development progress in duchenne muscular dystrophy. Front Pharmacol. 2022 Jul 22;13:950651. doi: 10.3389/fphar.2022.950651. PMCID: PMC9353054.
[6] Suthar R, Reddy B, Malviya M, Sirari T, Attri S, Patial A, Tageja M, Didwal G, Khandelwal N, Saini A, Saini L, Sahu J, Dayal D, Sankhyan N (2021) Bone density and bone health alteration in boys with duchenne muscular dystrophy: A prospective observational study. J Pediatr Endocrinol Metab 34:573–81. https://doi.org/10.1515/jpem-2020-0680
[7] Ronsley R, Islam N, Kang M, Nadel H, Reilly C, Metzger D, Selby K, Panagiotopoulos C (2020) Effects of Bisphosphonate Therapy on Bone Mineral Density in Boys with Duchenne Muscular Dystrophy. Clin Med Insights Endocrinol Diabetes 13. https://doi.org/10.1177/1179551420972400
[9] Growth reference data for 5-19 years (2007) World Health Organization. http://www.who.int/growthref/en/
[10] WHO Expert Committee on Physical Status: the Use and Interpretation of Anthropometry (1995) Physical status: the use of and interpretation of anthropometry, report of a WHO expert committee. World Health Organization. https://apps.who.int/iris/handle/10665/37003
[11] Cirillo D, Hart S, Reich R, Mason T (2018) Height Measures: Evaluating Alternatives to Standing Height in the Ambulatory Setting. Clin J Oncol Nurs 22:529–33. https://doi.org/10.1188/18.CJON.529-533
[12] ISCD (2019) Skeletal Health Assessment In Children from Infancy to Adolescence. Official Positions Pediatric. The International Society for Clinical Densitometry. https://iscd.org/learn/official-positions/pediatric-positions/
[13] Zemel BS, Kalkwarf HJ, Gilsanz V, Lappe JM, Oberfield S, Shepherd JA, Frederick MM, Huang X, Lu M, Mahboubi S, Hangartner T, Winer KK. Revised reference curves for bone mineral content and areal bone mineral density according to age and sex for black and non-black children: results of the bone mineral density in childhood study. J Clin Endocrinol Metab. 2011 Oct;96(10):3160-9. doi: 10.1210/jc.2011-1111. Epub 2011 Sep 14. Erratum in: J Clin Endocrinol Metab. 2013 Jan;98(1):420.
[14] Ward LM, Hadjiyannakis S, McMillan HJ, Noritz G, Weber DR (2018) Bone Health and Osteoporosis Management of the Patient With Duchenne Muscular Dystrophy. Pediatrics 142:S34–42. https://doi.org/10.1542/peds.2018-0333E
[15] Bierhals IO, dos Santos Vaz J, Bielemann RM, de Mola CL, Barros FC, Gonçalves H, Wehrmeister FC, Assunção MCF (2019) Associations between body mass index, body composition and bone density in young adults: findings from a southern Brazilian cohort. BMC Musculoskelet Disord 20:322. https://doi.org/10.1186/s12891-019-2656-3
[16] Davis J, Samuels E, Mullins L. Nutrition Considerations in Duchenne Muscular Dystrophy 2015. https://doi.org/10.1177/0884533615586202
[17] Tung JY, Lam T, Chan, SH (2021) Bone microarchitectural alterations in boys with Duchenne muscular dystrophy on long-term glucocorticoid treatment. J Bone Miner Metab 39: 606–611. https://doi.org/10.1007/s00774-020-01196-w
[18] Barzegar M, Elnaz N, Perinaz H, Shadi S, Sanaz T (2018) Bone mineral density and bone metabolism in patients with Duchenne muscular dystrophy. Iran J Child Neurol 12:77–83
[19] Klein GL (2015) The effect of glucocorticoids on bone and muscle. Osteoporos Sarcopenia 1:39–45. https://doi.org/10.1016/j.afos.2015.07.008
[20] Singh A, Schaeffer EK, Reilly CW (2018) Vertebral Fractures in Duchenne Muscular Dystrophy Patients Managed With Deflazacort. J Pediatr Orthop 38:320–4. https://doi.org/10.1097/BPO.0000000000000817
[21] Perera N, Farrar F (2015) Bone Health in Children with Duchenne Muscular Dystrophy: A Review. Pediatr Ther 5:3. https://doi.org/10.4172/2161-0665.1000252
[22] Lee SLK, Lim A, Munns C, Simm PJ, Zacharin M (2020) Effect of Testosterone Treatment for Delayed Puberty in Duchenne Muscular Dystrophy. Horm Res Paediatr 93:108–18. https://doi.org/10.1159/000508290
[23] Salera S, Menni F, Moggio M, Guez S, Sciacco M, Esposito S (2017) Nutritional challenges in duchenne muscular dystrophy. Nutrients 9:1–10. https://doi.org/10.3390/nu9060594
[24] Longui CA (2007) Glucocorticoid therapy: minimizing side effects. J Pediatr (Rio J) 83:163–71. https://doi.org/10.2223/jped.1713
[25] Wood CL, Cheetham TD, Hollingsworth KG, Guglieri M, Ailins-Sahun Y, Punniyakodi S, Mayhew A, Straub V (2019) Observational study of clinical outcomes for testosterone treatment of pubertal delay in Duchenne muscular dystrophy. BMC Pediatr 19:1–12. https://doi.org/10.1186/s12887-019-1503-x
[26] Larson CM, Henderson RC (2000) Bone mineral density and fractures in boys with Duchenne muscular dystrophy. J Pediatr Orthop 20:71–4. https://doi.org/10.1097/01241398-200001000-00016
[27] Mayo AL, Craven BC, McAdam LC, Biggar WD (2012) Bone health in boys with Duchenne Muscular Dystrophy on long-term daily deflazacort therapy. Neuromuscul Disord 22:1040–5. https://doi.org/10.1016/j.nmd.2012.06.354
[28] King WM, Kissel JT, Visy D, Goel PK, Matkovic V. Skeletal health in Duchenne dystrophy: Bone-size and subcranial dual-energy X-ray absorptiometry analyses. Muscle Nerve 2014;49:512–9. https://doi.org/10.1002/mus.23963
[29] Cruz-Guzmán OR, Rodríguez-Cruz M, Almeida-Becerril T, Maldonado-Hernández J, Baeza CW (2019) Muscle function and age are associated with loss of bone mineral density in Duchenne muscular dystrophy. Muscle Nerve 59:417–21. https://doi.org/10.1002/mus.26416
[30] Takaso M, Nakazawa T, Imura T, Ueno M, Saito W, Shintani R, Takahashi K, Yamazaki M, Ohtori S, Okamoto M, Masaki T, Okamoto H, Okutomi T, Ishii K, Ueda Y (2010) Can the caudal extent of fusion in the surgical treatment of scoliosis in Duchenne muscular dystrophy be stopped at lumbar 5? Eur Spine J 19:787–96. https://doi.org/10.1007/s00586-010-1347-4
[31] Ma J, McMillan HJ, Karagüzel G, Goodin C, Wasson J, Matzinger MA, DesClouds P, Cram D, Page M, Konji VN, Lentle B, Ward LM (2017) The time to and determinants of first fractures in boys with Duchenne muscular dystrophy. Osteoporos Int 28:597–608. https://doi.org/10.1007/s00198-016-3774-5
[32] Crabtree NJ, Roper H, McMurchie H, Shaw NJ (2010) Regional Changes in Bone Area and Bone Mineral Content in Boys with Duchenne Muscular Dystrophy Receiving Corticosteroid Therapy. J Pediatr 156:450-455.e1. https://doi.org/10.1016/j.jpeds.2009.09.010
[33] Novotny SA, Warren GL, Lin AS, Guldberg RE, Baltgalvis KA, Lowe DA (2012) Prednisolone treatment and restricted physical activity further compromise bone of MDX mice. J Musculoskelet Neuronal Interact 12:16–23
[34] Crabtree NJ, Roper H, Shaw NJ (2022) Cessation of ambulation results in a dramatic loss of trabecular bone density in boys with Duchenne muscular dystrophy (DMD). Bone 154. https://doi.org/10.1016/j.bone.2021.116248